The year in cardiovascular medicine 2021: dyslipidaemia.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 34974612.
- Also identified by DOI 10.1093/eurheartj/ehab875.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The past year was an exciting time for clinical lipidology when we learnt more about existing therapies as well as therapies targeting novel pathways discovered through genetic studies. LDL cholesterol remained the main target and a variety of drugs to lower LDL cholesterol through different mechanisms were explored. Emerging evidence on the atherogenity of triglyceride-rich lipoproteins led to renewed interest in lowering them with new treatments. Lp(a) was back in focus with evidence on causality and new targeted therapeutics which dramatically lower Lp(a) levels. We will be able to personalise lipid lowering therapy further with this enriched armamentarium once we have the results of the cardiovascular outcome studies with some of these new agents.
Medical subject headings
- Cardiovascular Agents
- Cardiovascular Diseases
- Dyslipidemias